Anvisa
Anvisa approves cannabis cultivation for medical purposes
በAI የተዘገበ በ AI የተሰራ ምስል
The National Health Surveillance Agency (Anvisa) approved, on January 28, 2026, resolutions allowing cannabis cultivation for health treatments and research, along with new administration routes and plant imports. This step marks progress in the national production chain, easing access to plant-derived medicines. The changes broaden options for patients with severe illnesses while upholding strict restrictions.
Brazil's National Health Surveillance Agency (Anvisa) has approved lenacapavir, sold as Sunlenca, for use as pre-exposure prophylaxis (PrEP) against HIV-1. The drug, given via subcutaneous injection every six months, demonstrated up to 100% efficacy in clinical trials with vulnerable populations. The approval paves the way for regulatory steps that could lead to its availability in the Unified Health System (SUS).
በAI የተዘገበ
Brazil's National Health Surveillance Agency (Anvisa) approved the drug lecanemabe, marketed as Leqembi, on Thursday, January 8, for patients with early-stage Alzheimer's. The monoclonal antibody, administered via infusion, slows disease progression in individuals with mild cognitive impairment and confirmed beta-amyloid protein in the brain. The approval marks progress, though it is not a cure.